Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970 - Wikidata - awgldk - TriplyDB

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

http://www.wikidata.org/entity/Q34221860

about

DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer Targeting the Checkpoint to Kill Cancer Cells Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.Targeting lung cancer through inhibition of checkpoint kinases.A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.ATR Kinase Inhibition Protects Non-cycling Cells from the Lethal Effects of DNA Damage and Transcription Stress.ATM protein is deficient in over 40% of lung adenocarcinomas.Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.Molecular Pathways: Targeting ATR in Cancer Therapy Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.Targeting the ATR-CHK1 Axis in Cancer Therapy The cell cycle checkpoint inhibitors in the treatment of leukemias.The Future of Radiobiology.ATR/CHK1 inhibitors and cancer therapy.Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.HUS1 regulates in vivo responses to genotoxic chemotherapies.Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.DNA repair pathways and cisplatin resistance: an intimate relationship The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation

P2860

Q26776513-C432E85B-471C-49E2-B192-20AF059534E2 Q26795781-1092298E-5CD0-40CB-9892-E882A3D9CA07 Q34456932-DF54BB72-B347-41AB-9558-8D5EBF30DD95 Q34614944-72D8C1E9-CAAC-47C2-8EEE-1EE9742189D7 Q35128547-8F664FEF-D122-426F-B28E-7B619F2FC9BE Q35627868-86BDEDB7-8DB2-4649-97BF-DB5669EB939C Q35799909-5C3B4B11-8B81-4B36-80B0-89DE19F795A8 Q36188973-FBFE285C-D03A-46CF-AF3D-40C272BF3D13 Q36544857-E6311F72-9A34-495A-9693-2C4CB9FC01EF Q36688959-E2CD452F-52CA-4D76-B71C-608AC6671CFB Q36739002-C7229E91-32D9-421E-AEF5-8275F66126D5 Q36855596-5C4813C1-D739-4B13-B1BC-F292D9B87EE5 Q36884873-87A3CD57-558B-4629-A9BD-D8D019B938D1 Q37628924-D5D7D91B-FC7B-44DA-8190-70F5E0F80E4A Q37630747-F4B45054-E1D3-4D19-A597-AE16B472F298 Q37634102-42C4C012-68F6-4DB8-AD91-87587A2BF962 Q37635766-171701FD-FE29-420F-8429-15F6121B8FC1 Q38261022-F3BEE76C-5EFF-4BAD-A3C2-2D028306FFA3 Q38523589-841E5C5B-B5B7-4AED-8100-01C00C8F2667 Q38585436-CE808636-6A6F-48E8-B06F-249AB4E14D1B Q38608688-41D9ABFE-0967-4F54-8D5F-B0F6CBF1425A Q38698806-E5D7F8AB-8C31-4019-9334-1205EE24D97B Q38702556-F3211ABD-FBDE-41B9-A21E-2B63FDCB3052 Q38817102-220A2B9E-B17A-48DA-A081-348935827695 Q38868502-3CCF0533-4CA7-49BD-BA7A-493F3DEEBE4A Q46136392-32E1C7C7-1CE3-486E-AE51-C91F67DE6D96 Q47622968-F5986334-59FD-425C-9A57-2A006474BFD1 Q47786231-BAB4B2E8-1B91-41B3-9534-B87F2D553E10 Q47829412-CF48B7A0-FD05-4BCA-8482-33DF5C5D4AAE Q48195510-A680FDB5-11A0-4243-8BB1-7F23EF560EB7 Q49679908-E3B1DA85-3F0A-44E4-84C9-3836376C6331 Q50958792-89FB1B62-84BC-4A40-ADAF-378A9707F9C2 Q51800946-67EE2F13-DEBC-44CD-8C19-F56F72670528 Q52428057-EC988FBB-1C0B-40B8-85D9-4F911FAEF99B Q55710290-2E6B8364-0D1D-4456-B4AD-4BF019A5A38B Q58699219-C509BAA7-5105-41B5-B6B5-EB577E9256E6 Q58734520-0BA1C0C6-A326-4561-A39B-AB7221C010E4

P2860

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

http://www.wikidata.org/entity/Q34221860

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@ast

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@en

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@nl

type

label

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@ast

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@en

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@nl

prefLabel

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@ast

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@en

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@nl

P1433

Q34221860-8EFD55F7-4EA6-4CFD-97C6-BE3C2ED14B98

P1476

Q34221860-5FFEFC8D-B2B0-4708-8130-0ECBE418C20C

P2093

Q34221860-0EF42CCC-B196-4573-80C8-887F1FE9C4D5

Q34221860-18717BEB-5768-4C19-B3D4-6EB9855C5344

Q34221860-1BD425CF-FE19-40AE-8E16-492BE5838FA8

Q34221860-2A64892F-4CA1-4310-8282-D15DF4EFF4C3

Q34221860-452DA657-F001-4AF8-A1AE-A2053EB64AC8

Q34221860-69CAC1BC-0BF8-459C-BAF2-A241606232A3

Q34221860-7582C08E-BAD4-4ABE-B682-CCCAB7B9F137

Q34221860-7DCFBD3D-A770-437B-9A32-D417ABB1F6E0

Q34221860-85908CFE-CCB3-4648-9D7F-0192C53EE0F1

Q34221860-866E9B02-17EC-4646-8098-62C78CF8173C

P2860

Q34221860-019A2BFB-3644-4DFE-82FA-00DFB4E31583

Q34221860-0830528F-CF09-476F-BC82-5A4A12192436

Q34221860-18070B81-AA55-4EB8-916F-F3CEEBAA7342

Q34221860-1A3C8AF3-9ADF-4D0F-8012-1211CCA6CA7C

Q34221860-1FD32FCA-9AE6-4C20-A45F-C86663F488AD

Q34221860-292A215D-CC8B-4F28-996A-D07201403603

Q34221860-2CD20F4D-15E0-4FF7-A043-0330F8664674

Q34221860-33961161-6DB4-4598-A4FF-FB1D1C267B27

Q34221860-3454D298-9847-4227-A1AE-4962BB8D3C10

Q34221860-348A8068-53C4-446B-874E-41AC01467CA2

P304

Q34221860-754A9D95-925D-49AF-A7DF-2543B8660DA7

P31

Q34221860-2CF604AB-5584-4C91-BA0E-E252485A5D50

P356

Q34221860-ECC383D4-2419-40E7-BCB2-59E13E1FB0C1

P407

Q34221860-FD6FF254-DE74-4570-A50C-882DD10BE478

P433

Q34221860-80D4DD56-CC43-4ED1-BC40-91DCB3C592E3

P478

Q34221860-06170282-40CB-4DE6-B1DE-CE629A9B0347

P577

Q34221860-8AD157F2-119B-4698-AAC6-821920C6F3A6

P5875

Q34221860-94518AB2-3F4E-4B27-9DA6-09FFB4AA58CB

P698

Q34221860-A5388696-9D73-45D8-BFBA-0BFF8D4357EA

P932

Q34221860-4913A100-FFB5-4952-853B-348AC0417E7A

P356

ONCOTARGET.2158

P1433

P1476

Potentiation of tumor response ...... selective ATR inhibitor VX-970

@en

P2093

Amy B Hall

http://www.w3.org/2001/XMLSchema#string

Brenda Eustace

http://www.w3.org/2001/XMLSchema#string

Brian Hare

http://www.w3.org/2001/XMLSchema#string

Brinley Furey

http://www.w3.org/2001/XMLSchema#string

Cheryl E Murphy

http://www.w3.org/2001/XMLSchema#string

Crystal Tolman

http://www.w3.org/2001/XMLSchema#string

Darin Takemoto

http://www.w3.org/2001/XMLSchema#string

Dave Newsome

http://www.w3.org/2001/XMLSchema#string

Diane M Boucher

http://www.w3.org/2001/XMLSchema#string

Jean-Damien Charrier

http://www.w3.org/2001/XMLSchema#string

P2860

A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging

The DNA-damage response in human biology and disease

Comprehensive molecular portraits of human breast tumours

Somatic mutations affect key pathways in lung adenocarcinoma

The combined status of ATM and p53 link tumor development with therapeutic response

PET imaging of proliferation with pyrimidines

MGMT gene silencing and benefit from temozolomide in glioblastoma.

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

Targeted cancer therapies based on the inhibition of DNA strand break repair

Comprehensive genomic characterization of squamous cell lung cancers.

P304

5674-5685

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2158

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263817389

http://www.w3.org/2001/XMLSchema#string

P698

25010037

http://www.w3.org/2001/XMLSchema#string

P932

4170644

http://www.w3.org/2001/XMLSchema#string